Univariate analysis | Multivariable analysis | |||||||
OS | rPFS | OS | rPFS | |||||
Subgroup | HR | P | HR | P | HR | P | HR | P |
Age: >70 y | 0.97 (0.55–1.72) | 0.926 | 1.00 (0.62–1.61) | 0.985 | NA | NA | NA | NA |
Karnofsky performance status: ≤80 | 2.94 (1.43–6.07) | 0.003 | 1.56 (0.94–2.60) | 0.088 | 2.71 (1.22–6.03) | 0.015 | 1.41 (0.81–2.46) | 0.221 |
Baseline PSA: >60 ng/mL | 2.59 (1.28–5.26) | 0.008 | 1.43 (0.86–2.39) | 0.173 | 0.96 (0.44–2.10) | 0.924 | 0.61 (0.32–1.15) | 0.125 |
Time from diagnosis to first 177Lu-PRLT treatment: >5 y | 0.70 (0.40–1.23) | 0.217 | 0.54 (0.33–0.88) | 0.013 | NA | NA | 0.49 (0.30–0.82) | 0.006 |
Cumulative administered activity: >16 GBq | 0.32 (0.18–0.58) | <0.001 | 0.81 (0.50–1.30) | 0.375 | 0.37 (0.20–0.69) | 0.002 | NA | NA |
Bone metastases: yes | 11.77 (1.61–86.20) | 0.015 | 2.29 (0.98–5.34) | 0.057 | 3.03 (0.38–24.15) | 0.295 | 1.13 (0.44–2.88) | 0.801 |
Visceral metastases: yes | 2.71 (1.50–4.89) | 0.001 | 1.55 (0.91–2.64) | 0.110 | 1.72 (0.92–3.24) | 0.090 | 0.97 (0.53–1.76) | 0.908 |
Baseline hemoglobin: ≤7.5 mmol/L | 4.61 (2.04–10.39) | <0.001 | 2.56 (1.45–4.50) | 0.001 | 2.76 (1.11–6.89) | 0.029 | 2.59 (1.26–5.33) | 0.010 |
Baseline ALP: ≥220 U/L | 1.84 (1.02–3.33) | 0.043 | 2.21 (1.33–3.65) | 0.002 | 1.20 (0.64–2.27) | 0.570 | 2.00 (1.14–3.50) | 0.015 |
HR = hazard ratio; NA = not applicable.
Data in parentheses are 95% CIs.